Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “SPACECRAFT GUIDANCE”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

1,065 records · Page 60
All sourcesNASA NTRSDOE OSTI
NASA NTRSDate not supplied

Integrated Design Results for the MSR SRC Mars Ascent Vehicle

The primary mission of the NASA Mars Sample Return (MSR) Campaign is to return samples of the Martian surface to Earth for scientific study. As part of this campaign, NASA is developing a Mars Ascent Vehicle (MAV). This vehicle must survive an approximate two-year journey to the Martian surface as a payload aboard a separate lander spacecraft. After residing on the surface for another year, the MAV will carry a payload of samples into orbit. From there, following ejection from the MAV, the samples will rendezvous with an Earth return spacecraft for capture, and ultimately, return to Earth. The design of the MAV represents a number of unique challenges, as no launch vehicle has ever left the surface of a planet other than Earth. Although conceptual designs for a MAV have been in various levels of development since the 1970s, none have achieved the level of fidelity and support that exists in the current MSR-MAV design. Early MSR-MAV concept studies examined multiple methods of propulsion, ultimately deciding that a Two-Stage-to-Orbit (TSTO) solid propulsion vehicle would provide the most capable performance in a Martian environment. Following this key architecture decision, the vehicle design was further matured to a Solid-Solid Guided-Guided (SSGG) architecture for NASA Key Decision Point A (KDP-A). Although the SSGG design was able to meet all mission constraints, concerns were raised regarding limited mass margin on other elements of the MSR campaign at such an early phase. A design challenge was issued to reduce MAV total mass by as much as possible. It was ultimately determined that by moving a number of components of the vehicle second stage to the first stage, the overall vehicle mass could be reduced significantly. The new design features a much smaller and completely unguided second stage. This paper describes the resultant Solid-Solid Guided-Unguided (SSGU) MAV design concept developed as part of the Systems Requirement Cycle (SRC). This design was developed primarily by NASA Marshall Space Flight Center (MSFC), in association with NASA Jet Propulsion Laboratory (JPL) and NASA Langley Research Center (LaRC). The TSTO vehicle includes one solid rocket motor per stage. As the vehicle second stage is unguided, it features spin-stabilization to maintain vehicle stability during flight. An electromechanically actuated Thrust Vector Control (TVC) system and a monopropellant Reaction Control System (RCS) are employed for active guidance on the first stage. The vehicle is designed to deliver up to 0.47kg of Martian samples to a Mars circular orbit of 380km at 27° inclination. Due to the extremely unique design constraints of this mission, and a recent transition to a Risk Class A posture, the MAV team was compelled to devise unconventional solutions to the vehicle design. The detailed design and analysis of these subsystems and the vehicle as a whole are discussed in this paper relative to all of the engineering disciplines involved.

MAV↗
NASA NTRS2004

Global Geospace Science (GGS)/POLAR Thermal Ion Dynamics Experiments (TIDE) Co-Investigator Program: Mission Operations and Data Analysis (MO/DA)

We have pursued several investigations using the Polar/TIDE data set. The first was a comparison of TIDE high-altitude observations with similar ion flux signatures in the Los Alamos National Laboratory (LANL) magnetospheric plasma analyzer (MPA) data. There are several geosynchronously orbiting satellites with LANL MPA instruments onboard. When the satellite is immersed in fresh plasma sheet electrons, the spacecraft voltage drops to several hundred volts negative, and cold ions are accelerated in to the detector. In the LANL MPA spectrograms, the accelerated cold ions appear as a bright, narrow line, following the voltage of the spacecraft. This "ion line" is seen regularly on the nightside, but has not received much attention. The Polar TIDE observations indicated a ubiquitous "lobal wind" in the near-- magnetotail, a field-aligned stream of approx. 100 eV ions flowing out of both polar ionospheres. The interesting result of this research is that the MPA ion line is also peaked in the field-aligned direction, even though the potential well should be uniform in all directions. It is believed that this is evidence that the lobal winds not only populate the high-latitude lobes, but fill the lobes all the way in to the near-Earth plasma sheet (the location of geosynchronous orbit). This activity developed into a full-scale survey of the lobal wind observations in the TIDE database. The universality of these observations with respect to local time and solar wind conditions implies that the ionospheric outflow is supplying the near-Earth plasma sheet at all times, regardless of magnetic activity. We have conducted a statistical study of the characteristics of the lobal wind in these two data sets FIDE and LANL MPA), finding much similarity between them. Using these characteristics as input conditions to our inner magnetosphere ion transport model, we have conducted simulations of the flow of these particles inside of geosynchronous orbit to show the impact these particles will have on the near-Earth space environment. As the study has progressed, these results have been presented several times to the TIDE team during teleconferences. It is planned to present this survey at the GEM 2004 Summer Workshop, and hopefully at additional conferences in the near future. We are presently writing a paper on the lobal wind occurrence statistics, which should be submitted in April or May to the Journal of Geophysical Research for publication. An undergraduate student at the University of Alabama in Huntsville, Will Maddox, working at NASA MSFC with Dr. Paul Craven, is presently creating a database of the values TIDE moments for the lobal wind (under Dr. Liemohn's guidance), and this will be the focus of a follow-on paper.

Nagy, Andrew↗
NASA NTRSDate not supplied

Improving Efficacy and Safety of Pharmacological Treatment Through Precision Medicine and Pharmacogenomics for Human Deep Space Exploration

INTRODUCTION: Future spaceflight will require increased crew medical autonomy as exploration class missions expanding duration and distance from Earth, especially for Mars missions. As mission duration increases, it will be even more essential to have appropriate amounts of effective medication to ensure the maintenance of crew health and performance. Conversely, mass and volume constraints will become more severe as future spaceflight expands beyond low Earth orbit, where resupply is difficult or becomes impossible. These constraints thus convey an urgency to further tailor medications included in the spacecraft formulary and increased examination of appropriate dosing regimens. BACKGROUND: Precision Health is an exciting area of cutting-edge research and medicine focused on maintaining an individual’s health and performance through in-depth understanding of an individual’s unique factors and molecular profiles. This approach can be adapted to better predict, monitor, and address physiological responses to the spaceflight environment. One example is the field of pharmacogenomics (PGX),the study of how the expressed genome impacts drug responses with the goal of prescribing the right dose of the right drug at the right time. Specifically, PGX testing provides valuable information on an individual’s precise allelic variations to guide physicians in making informed decisions on pharmaceutical choice and dosing to avoid adverse drug events and maximize pharmacological efficacy. The goal of this study was to evaluate which drugs in the current space pharmacy could be evaluated using PGX testing and to understand the potential impact on the health and wellness of the astronaut population. Additionally, we sought to evaluate clinically available FDA-approved PGX testing solutions to better understand its applicability. METHODS: A complete list of drugs onboard the International Space Station (ISS) was analyzed for risk and likelihood of drug failure and PGX actionability. This analysis encompassed both personal astronaut medications, including supplements and over the counter drugs (n=151) and ISS MedKit formulary medications (n=95). Duplicate medications and different formulations were removed, which resulted in 157 total drugs used in the subsequent analysis. A 5x5 risk assessment table was produced by examining the likelihood of drug failure compared to the consequence of drug failure. Likelihood of individual drug failure was defined by whether existing processes are sufficient to prevent adverse events, as ranked from 1 (very low, can easily be prevented) to 5 (very high, cannot be prevented) during a Mars mission. In contrast, the consequence of drug failure was defined by impact to safety, schedule, cost or technical and ranked from 1 (very low) to 5 (very high).A comprehensive assessment of commercially available PGX solutions is currently underway to evaluate specimen requirements, cost/benefit analysis (cost vs. number of alleles assessed), utility of variant analysis, relevance to inflight medication usage, quality of reporting in enabling clinical application, and ease of integration into electronic medical records. RESULTS: Risk assessments(LxC 5x5 table) indicated29medicationswere in the yellow or red zone driven predominantly by drug failure or safety concerns, with the remainder(n=128)of the medications in the green zone where risk is acceptable. We found that current PGX testing results could impact 21% of the total medications in the ISS MedKit and IMAK; of these, 9 medications currently have direct clinically actionable guidance available. Results of the clinical PGX solution evaluations as related to these medications will be presented. CONCLUSION: PGX testing has demonstrated clear benefits in terrestrial medicine and clinical environments for the selection of proper medications, avoiding adverse drug reactions, and maximizing drug efficacy. We propose that similar benefits would be bestowed on the astronaut and commercial spaceflight passenger population by performing preemptive pre-flight PGX testing to reduce risk of mission failure due to ineffective or toxic medications, improve targeting drug efficacy and safety, and further open the door to countermeasure research exploring PGX-related allelic variants. For example, PGX results could allow tailoring of specific medications at optimal doses more precisely to each individual astronaut, particularly in areas of space motion sickness, sleep aids, and analgesics. An additional benefit is that PGX results could provide information for better planning of the components of a space pharmacy for deep space missions to be more cost effective and more efficient in the utilization of limited pharmaceutical resources. Finally, while PGX testing of the astronaut corps is not currently conducted, this approach could provide immediate impact in support of mission success by reducing risks, optimizing astronaut performance, and providing valuable insights into long-term astronaut health. Such advancements in clinical decision making are important next steps in building dynamic individual risk profiles for astronauts, increasing crew autonomy and providing tailored countermeasures

Alice R W Tang↗